Prenylated Tetrahydroquinoline PPAR Agonists for Reduced Adverse Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new PPAR agonists that provide safer, more effective treatment options for PPAR-mediated diseases with improved benefit/risk ratios, allowing for personalized therapies based on patient profiles, as existing treatments have adverse effects and limited efficacy.
Innovation Solution
Development of prenylated tetrahydroquinoline and quinoline compounds with pan-PPAR, dual PPARα/γ, or selective PPARα agonist activities, which reduce cholesterol levels, regulate inflammation, and have low cytotoxicity, formulated into pharmaceutical compositions for various administration routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If potent PPARγ agonists (glitazones) are used to treat type 2 diabetes, then glucose homeostasis is improved, but serious adverse effects occur including cardiovascular risk, hepatotoxicity and bladder cancer
Solution Approach 1:
The patent applies local quality by designing compounds with selective PPARγ agonist activity that provides sufficient glucose control while limiting excessive activation that causes adverse effects. The prenylated tetrahydroquinoline and quinoline structures are engineered to interact specifically with PPARγ to achieve therapeutic effect without the harmful over-activation seen with potent glitazones.
Solution Approach 2:
The patent changes the chemical structure parameters by using prenymlsted tetrahydroquinoline and quinoline cores instead of traditional glitazone structures. This structural parameter change results in compounds with modified binding characteristics to PPARγ, achieving a balance between efficacy and safety that addresses the adverse effect profile of existing potent PPARγ agonists.
2Reliability
If dual PPARα/γ agonists (glitazars) are used to treat metabolic syndrome, then lipid and glucose metabolism are improved, but adverse effects occur due to potent PPARγ agonism
Solution Approach 1:
The patent applies local quality by creating compounds with balanced PPARα and PPARγ agonist activities. The prenymlsted tetrahydroquinoline and quinoline structures are designed to provide moderate PPARγ activation combined with PPARα activation, achieving metabolic syndrome treatment benefits while avoiding the adverse effects associated with potent PPARγ agonism alone.
3Adaptability or versatility
If new PPAR agonist structures are developed to improve safety and efficacy, then treatment options are increased, but development complexity and time are extended
Solution Approach 1:
The patent applies universality by developing a series of prenymlsted tetrahowquinoline and quinoline compounds that can function as selective PPARα agonists, selective PPARγ agonists, or dual PPARα/γ agonists depending on the specific substituents. This multi-functional approach allows a single chemical scaffold to address multiple PPAR-mediated conditions with different therapeutic needs.
Solution Approach 2:
The patent uses parameter changes by systematically varying substituents on the prenymlsted tetrahowquinoline and quinoline core structures to modulate PPAR selectivity and activity. This allows optimization of compounds for specific indications while maintaining a manageable development framework based on a common chemical scaffold.
Data Source
Figure 1~2B
Figure 3A~3B
Figure 4A~4F
AI summary
Prenylated tetrahydroquinolines and quinolines and pharmaceutical compositions comprising the same. Prenylated tetrahydroquinoline and quinolines and pharmaceutical compositions comprising the same, for use in the prevention and/or treatment of peroxisome proliferator-activated receptor (PPAR)-mediated diseases such as metabolic syndrome, type 2 diabetes mellitus, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, dyslipidemic atherosclerosis, metabolic dysfunction-associated fatty liver disease (MAFLD), cardiovascular disease, cardiometabolic disease, neurodegenerative disease, Friedreich's ataxia, Parkinson's disease, multiple sclerosis, Alzheimer's disease, autoimmune disease, rheumatoid arthritis, autoimmune thyroid disease, dermatological disease, and cancer.